The 12-month open-label extension of TPIP in PAH patients showed sustained and clinically meaningful improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved asymptomatic status, and 65% reached refined low-risk, s…
The 12-month open-label extension of TPIP in PAH patients showed sustained and clinically meaningful improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved asymptomatic status, and 65% reached refined low-risk, supporting TPIP's potential as a leading PAH therapy.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
